Reimbursement hurdles hinder Entresto use in HFrEF

ORLANDO – Use of sacubitril/valsartan to treat patients with heart failure with reduced ejection fraction (HFrEF) became a class I recommendation in both the U.S. and European heart failure...
Source: Hospitalist News - Category: Hospital Management Source Type: research